Repligen (RGEN) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $167.49 --0%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
SURG, PASG, CIRC, More
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
SURG, PASG, CIRC, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $15.3 million versus the consensus estimate of $15.6 million.
Repligen sees FY2014 revenue of $60-62 million, versus prior guidance of $59-62 million and the consensus of $0.28 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
